Hello, everyone, and welcome to the middle of the week. You made it this far, so why not acknowledge the moment with a non-carcinogenic cup of stimulation? After all, consider the alternatives. Before we continue, we would like to note that we will take an extended break to attend to a milestone for the shortest of our short people. We will return next week. Meanwhile, we hope you have a productive couple of days and a delightful weekend. And now, here are some tidbits. Stay well, y’all …
The American Diabetes Association let hundreds, possibly thousands, of attendees see new study data on Novo Nordisk’s Victoza diabetes drugs more than an hour before its official release to the public and the markets, Bloomberg News says. The attendees were asked not to tweet the info, but — surprise! — some folks tweeted pictures of charts within minutes.
Federal incentives to drug makers have helped lead to at least seven late-stage antibiotics that may fight bacteria that can become dangerous superbugs, the Wall Street Journal writes. “We have built a robust portfolio of broad-spectrum antibiotics that possess activity” against the microbes, Richard Hatchett, acting director of the government’s Biomedical Advanced Research and Development Authority, told lawmakers.
Using the NEJM embargo policy as an example, these policies have been liberalized to the extent that admonitions coming from the organizers of scientific meeting have no teeth, as these tweets or any other news coming out of a meeting have no chance of jeopardizing publication.
@Ed, this product is commercially available from the UK (home of James Bond), link below.
Tweeting is pretty low tech, and hypothetically they could confiscate your cell phone at the hallway entrance. Better to purchase a pair of eyeglasses with a built in spy lens, which will photograph a presentation surreptitiously and transmit the images wirelessly from a device on your belt hidden under your coat to whomever is set up to receive them, maybe your stock broker if you’re of that persuasion.
I kind of like that idea. Who’s developing that?
Comments are closed.